ENMD 0995

Drug Profile

ENMD 0995

Alternative Names: S 3APG

Latest Information Update: 07 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation; Childrens Hospital Boston
  • Class Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma

Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 07 May 2007 Discontinued - Phase-I for Multiple myeloma in USA (PO)
  • 19 Apr 2004 A clinical study has been added to the adverse events section
  • 18 Dec 2003 Data presented at the e45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the adverse events and Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top